MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
On Tuesday, SAB BIO (NASDAQ:SABS) released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its primary safety and pharmacodynamic ...
A virtual AGM has been called for SAB Zenzele shareholders to vote in the new scheme on 10 May 2021. The virtual AGM event will be live-streamed on the SAB Zenzele Kabili app and broadcast live on ...
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” Forward-Looking ...
SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results